Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have earned a consensus rating of “Hold” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $7.1429.

Several analysts recently issued reports on NMRA shares. Mizuho increased their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Tuesday, September 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Saturday, September 27th.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NMRA. CWM LLC boosted its position in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company’s stock valued at $25,000 after buying an additional 24,864 shares during the last quarter. Jump Financial LLC purchased a new position in Neumora Therapeutics in the 1st quarter valued at about $25,000. Catalyst Funds Management Pty Ltd purchased a new position in Neumora Therapeutics in the 2nd quarter valued at about $29,000. Aigen Investment Management LP purchased a new position in Neumora Therapeutics in the 1st quarter valued at about $36,000. Finally, Virtu Financial LLC purchased a new position in Neumora Therapeutics in the 1st quarter valued at about $40,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Stock Up 2.8%

Shares of NASDAQ NMRA opened at $1.83 on Friday. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $17.19. The company has a market cap of $296.37 million, a P/E ratio of -1.17 and a beta of 2.92. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average price of $1.70 and a 200 day moving average price of $1.19.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05. Research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.